Posted by Michael Wonder on 11 Apr 2018
Redistribution of UK’s portfolio of centrally authorised products
11 April 2018 - Assignment of new rapporteurs and co-rapporteurs completed.
The EU27 Member States and the EMA have completed the reallocation of the medicines for which the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) and Veterinary Medicines Directorate (VMD) are currently rapporteur or co-rapporteur appointed by the scientific committees to coordinate the evaluation of a medicine.
Over 370 centrally authorised products have been transferred to new rapporteurs and co-rapporteurs from the EU27 Member States, plus Iceland and Norway, following a methodology developed by EMA’s working groups on committees’ operational preparedness for human and veterinary medicines.
